ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      AI Subscribe Login/Register Profile Icon
      S&P 500
      5,985.38
      0.00%
      US Tech 100
      20,467.20
      -0.11%
      Dow Jones
      43,958.19
      0.00%
      Brent Oil
      72.97
      1.54%
      Bitcoin
      91,056.67
      0.54%
      Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. Aldeyra Therapeutics Inc (ALDX)

      7. Aldeyra Therapeutics Inc (ALDX) News

      Aldeyra Therapeutics Inc

      Aldeyra Therapeutics Inc (ALDX)

      NASDAQ
      4.41
      -0.35
      (-7.26%)
      Closed November 13 4:00PM
      Delayed by 15 minutes
      4.50
      0.09
      ( 2.04% )
      Pre Market: 8:35AM
      Delayed by 15 minutes

      Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

      Premium

      ALDX News

      Official News Only

      Form 424B5 - Prospectus [Rule 424(b)(5)]
      Edgar (US Regulatory)
      August 01 2024
      ALDX (-7.26%)

      Form 8-K - Current report
      Edgar (US Regulatory)
      August 01 2024
      ALDX (-7.26%)

      Form 10-Q - Quarterly report [Sections 13 or 15(d)]
      Edgar (US Regulatory)
      August 01 2024
      ALDX (-7.26%)

      Form 8-K - Current report
      Edgar (US Regulatory)
      June 20 2024
      ALDX (-7.26%)

      Form 8-K - Current report
      Edgar (US Regulatory)
      June 13 2024
      ALDX (-7.26%)

      Form 8-K - Current report
      Edgar (US Regulatory)
      June 07 2024
      ALDX (-7.26%)

      Form 4 - Statement of changes in beneficial ownership of securities
      Edgar (US Regulatory)
      June 06 2024
      ALDX (-7.26%)

      Form 4 - Statement of changes in beneficial ownership of securities
      Edgar (US Regulatory)
      June 06 2024
      ALDX (-7.26%)

      Form 4 - Statement of changes in beneficial ownership of securities
      Edgar (US Regulatory)
      June 06 2024
      ALDX (-7.26%)

      ALDX Discussion

      View Posts
      jgrabar jgrabar 2 months ago
      Current Aldeyra shareholders who have continuously held Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) shares since prior to January 7, 2021 should click here: https://grabarlaw.com/the-latest/aldeyra-sahreholder-investigation/ to learn more. You can seek corporate reforms, the return of funds back to company coffers, and a court approved incentive award at no cost to you whatsoever.
      👍️0
      TechandBio TechandBio 2 months ago
      Another big winner for me this year ICCM is next!

      $ALDX
      👍️0
      Investor2014 Investor2014 3 months ago
      Sold half at around $5’ish for about 50% profit looking to buy back lower awaiting NDA filing and like decision dates for Reproxalap.
      👍️0
      peterus peterus 3 months ago
      what your thoughts here for the future?
      👍️0
      peterus peterus 3 months ago
      hi bro you know a good discord or web for parma and bio´s
      👍️0
      peterus peterus 3 months ago
      when offering lol
      👍️0
      Investor2014 Investor2014 3 months ago
      No one happy here?
      👍️0
      Investor2014 Investor2014 3 months ago
      Will the dry eye confirmatory P3 trial prove successful this morning? Hard to call, but leaning towards yes.
      👍️0
      Monksdream Monksdream 8 months ago
      ALDX under $4
      👍️0
      jgrabar jgrabar 8 months ago
      NOTICE TO LONG-TERM ALDEYRA THERAPEUTICS, INC. (NASDAQ: ALDX) INVESTORS

      Grabar Law Office is investigating claims on behalf of Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) shareholders. The investigation concerns whether certain officers of FMC have breached their fiduciary duties owed to the company.

      Current Aldeyra shareholders who have continuously held Aldeyra shares since prior to January 7, 2021 should click here: https://grabarlaw.com/the-latest/aldeyra-sahreholder-investigation/. You can seek corporate reforms, the return of funds back to company coffers, and a court approved incentive award at no cost to you whatsoever.

      Why: A recently filed securities fraud class action complaint alleges that Aldeyra Therapeutics, through certain of its officers and directors, made materially false and misleading statements regarding the Company's business, operations, and prospects. Specifically, it is alleged that the Company made false and misleading statements about or failed to disclose: (i) the ADX-2191 new drug application (“NDA”) did not include adequate and well-controlled investigations and thus failed to show substantial evidence of ADX-2191's effectiveness; (ii) as a result, the FDA was unlikely to approve the ADX-2191 NDA in its current form; (iii) accordingly, Aldeyra had overstated ADX-2191's clinical and/or commercial prospects; and (iv) as a result, Aldeyra’s public statements were materially false and misleading at all relevant times.

      If you have continuously held Aldeyra shares since prior to January 7, 2021, you are encouraged to visit https://grabarlaw.com/the-latest/aldeyra-sahreholder-investigation/, contact Joshua H. Grabar at jgrabar @FH-6085.
      👍️0
      InvestorPhilia4 InvestorPhilia4 8 months ago
      Still progressing here. I think they have been prudent, of late... with the AbbVie option agreement for Reproxalap and other shots on goal without partners. There is certainly upside with continued clinical success. Any updated views on Aldeyra?
      👍️0
      Monksdream Monksdream 11 months ago
      Early Barchart 100
      https://www.barchart.com/stocks/performance/percent-change/advances?timeFrame=today&viewName=main&screener=overall&orderBy=percentChange&orderDir=desc
      👍️0
      InvestorPhilia4 InvestorPhilia4 1 year ago
      I added 3,500 shares on 10/16 as well below $1.80. I wish I leaned in more. I am a holder and still see long-term upside from here.
      👍️0
      Invest-in-America Invest-in-America 1 year ago
      ALDX: Just crossed the (dangerous) 1.5-Hrs-Into-The-Open-Rubicon, and movin' UP from there!! (Not easy to do for ANY stock.)
      👍️0
      green maschine green maschine 1 year ago
      Nice grab. It's good to be the early bird. I knew nothing about the company, just saw the news.
      👍️0
      Invest-in-America Invest-in-America 1 year ago
      Me too, Dude. (And this Firm has worked on this drug for a long time; and that ain't NO 'small-potatoes' Company that just partnered with them either.)

      👍️0
      green maschine green maschine 1 year ago
      Yep. I snatched up some of this pre-market.
      👍️0
      Invest-in-America Invest-in-America 1 year ago
      ALDX: Could have a good day here; 'Dry Eye' syndrome afflicts MILLIONS worldwide!
      👍️0
      Investor2014 Investor2014 1 year ago
      I bought to average down today, it seems a sensible move.
      👍️0
      InvestorPhilia4 InvestorPhilia4 1 year ago
      With the pending readouts and relatively short trials that may provide additional support, I agree.

      Also, the company has some breathing room with > $2 per share in cash after all liabilities as of 6/30 and only burning ~ $0.20 per share quarterly.

      The current sub $2 share price looks attractive to me.
      👍️0
      Investor2014 Investor2014 1 year ago
      Ouch indeed, but it isn’t over for dry eye and we are expecting one other different P3 indication readout this year.
      👍️0
      InvestorPhilia4 InvestorPhilia4 1 year ago
      Ouch
      👍️0
      Investor2014 Investor2014 1 year ago
      A not so great day yesterday for $ALDX.

      Small potential indication costing the 25% run up we have in expectation of H2 events.

      It isn’t over for ADX-2191 yet though…
      👍️0
      InvestorPhilia4 InvestorPhilia4 2 years ago
      I have been invested here (smaller position than in AVXL) also. Binary/inflection points appear to be ahead mid-2023. We appear to have several shots on goal.
      👍️0
      Investor2014 Investor2014 2 years ago
      Yet another great day for aldeyra.

      No one invested here?
      👍️0
      Investor2014 Investor2014 2 years ago
      Another great day for Aldeyra. In due course probably pay handsomely.
      👍️0
      Investor2014 Investor2014 2 years ago
      Good day for Aldeyra!
      👍️0
      Investor2014 Investor2014 3 years ago
      That’s biotech.
      👍️0
      TheFinalCD TheFinalCD 3 years ago
      what I meant was the time line

      mid 2022

      👍️0
      Investor2014 Investor2014 3 years ago
      Agree and believe that is what I just said.
      👍️0
      TheFinalCD TheFinalCD 3 years ago
      yeah but heres the kicker

      ALDX
      Primary Endpoint of TRANQUILITY-2 Trial Modified to be Met if Either Ocular Redness or Schirmer Test Achieved; Target Enrollment Increased from 300 to up to 400 Patients; Top-Line Results Expected Mid-2022
      👍️0
      Investor2014 Investor2014 3 years ago
      So TRANQUILITY-2 endpoints to be changed to meet either Redness or Schirmer for potential approval.

      Could be fine not least given that secondary p-value.

      Still hope!
      👍️0
      TheFinalCD TheFinalCD 3 years ago
      ALDX NEWS https://www.streetinsider.com/Business+Wire/Aldeyra+Therapeutics+Announces+Top-Line+Results+from+the+Phase+3+TRANQUILITY+Trial+in+Dry+Eye+Disease/19374659.html
      👍️0
      Investor2014 Investor2014 3 years ago
      Yeah not good.
      👍️0
      TheFinalCD TheFinalCD 3 years ago
      NEWS HALT ))) 12/20/2021 16:00:34 ALDX Aldeyra Therapeutics Cmn Stk NASDAQ
      T1
      👍️0
      Investor2014 Investor2014 3 years ago
      Looks like the market finally clicked that ocular redness is the primary endpoint over the conventional Schirmer’s test as agreed by the FDA trial protocol.

      👍️0
      Rayn_Makr Rayn_Makr 3 years ago
      ADX-1612 and ADX-1615, Chaperome Inhibitors

      Last summer I dove into the mechanism of action for ADX-1612 and spent a fair amount of time looking at HSP90 on PubMed. It is a widely recognized target. It will be interesting to see how the numerous assets at ALDX are managed. It's challenging to put a market cap and time to reach that value but they have great potential, no doubt. Current market conditions will probably make for a wild ride. Good Luck!

      https://pubmed.ncbi.nlm.nih.gov/?term=hsp90+inhibitor
      👍️0
      Investor2014 Investor2014 3 years ago
      I agree, ALDX has great potential.
      👍️0
      Rayn_Makr Rayn_Makr 3 years ago
      RASP-INHIBITION IN SYSTEMIC DISEASES

      ADX-629 became a topic in the recent conference call so I did a revisit of that therapeutic. Glad I did since ADX-629 offers an impressive opportunity to further RASP inhibition. Several nuggets to pass along from a quick review of ADX-629:

      The clinical trial NCT04847544 for Treatment of COVID-19 was initiated in April. It is recruiting N=30 and estimated completion this year.

      https://clinicaltrials.gov/ct2/show/NCT04847544?term=aldeyra&recrs=abdf&draw=2&rank=1

      Secondly, the phase 1 results showed target engagement "Also Improved Lipid Profiles". Lipid therapeutics have a large market, i.e., cardiovascular disease. Look at slide #17.

      https://ir.aldeyra.com/static-files/33742ce3-ebdc-4569-9f65-b5b7bd8c73eb

      The asthma trial is also on the trial list.

      https://clinicaltrials.gov/ct2/results?term=aldeyra&recrs=b&recrs=a&recrs=f&recrs=d&age_v=&gndr=&type=&rslt=&Search=Apply%5D

      Six ongoing clinical trials explains the recent raise in capital and great timing on that. Kudos to management!
      👍️0
      Rayn_Makr Rayn_Makr 4 years ago
      Perceptive Advisors SEC form 4
      3 May 2021 shows 1,200,000 shares bought at $12.50 = $15,000,000
      They now have a total of 9.9 million shares which at $12.50 = $123,750,000. They have been adding since July 2020. Safe to say they have a positive outlook, eh?
      👍️0
      Investor2014 Investor2014 4 years ago
      It will stay above the $12.50 offer price just like last time especially given the great P3 trial readout.
      👍️0
      make it happen make it happen 4 years ago
      I wouldn't touch this personally with a ten foot stick for a while not bashing but that's a heck of a lot of dilution coming out. 125 million dollars and able to add a lot more.
      👍️0
      Investor2014 Investor2014 4 years ago
      Bought in again @$12.89.
      👍️0
      make it happen make it happen 4 years ago
      Huge $125,000,000 offering & can add another $18,750,000 million
      👍️0
      make it happen make it happen 4 years ago
      Most def
      👍️0
      Investor2014 Investor2014 4 years ago
      Sold today avg $15.07. Figured they’d needmore funding and the price would dip waiting for a NDA filing and next P3 readout in H2.

      Plenty time to buy back in cheaper, which should be a nice long term hold.
      👍️0
      ClayTrader ClayTrader 4 years ago
      * * $ALDX Video Chart 04-27-2021 * *

      Link to Video - click here to watch the technical chart video

      👍️0
      make it happen make it happen 4 years ago
      Good volume. When it slows it'll fade hard imho Wish could get locates some where. 4x highest volume day ever
      👍️0
      altruism altruism 4 years ago
      Billion dollars traded today so far
      👍️0
      make it happen make it happen 4 years ago
      Yes, usually have something going on or at least some kind revenues from something. Not just spending money.
      👍️0

      Your Recent History

      NASDAQ
      ALDX
      Aldeyra Therapeutics
      Delayed Upgrade Clock